The outperformance was driven by a strong showing across all segments (except active ingredients) over the year-ago June quarter and over the preceding March quarter. Gains were made by the US specialty business, there was recovery in the branded generic portfolio in India besides some benefit from Covid-related drugs.
ET Intelligence Group: India’s largest pharma company reported a remarkable performance in the first quarter of this fiscal — satisfying investors who have been waiting to see the company deliver a strong show. The evidence was the 10% jump in the stock following the announcement of results on Friday.
The outperformance was driven by a strong showing across all segments (except active ingredients) over the year-ago June quarter and over the
- GIFT ARTICLE
- FONT SIZE
Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors
Stock analysis. Market Research. Industry Trends on 4000+ Stocks
Clean experience with
Comment & Engage with ET Prime community
Exclusive invites to Virtual Events with Industry Leaders
A trusted team of Journalists & Analysts who can best filter signal from noise